Form 4: Theravance Biopharma Executive Rhonda Farnum Reports Changes in Beneficial Ownership
SEC Form 4 Filing
Rhonda Farnum, SVP, COMM & MEDICAL AFFAIRS at Theravance Biopharma, reports the vesting of performance-based restricted stock units and shares withheld for tax obligations.
Summary
- Rhonda Farnum, a Senior Vice President at Theravance Biopharma, filed a Form 4 detailing changes in her beneficial ownership of the company's stock.
- On February 10, 2025, 5,283 performance-based restricted stock units (RSUs) vested, becoming eligible to vest based on continued service.
- These RSUs were granted on April 2, 2024, and their vesting was contingent on achieving certain performance conditions.
- On February 20, 2025, 15,810 shares were withheld to cover tax obligations related to the vesting of previously granted RSUs at a price of $9.66.
- Following these transactions, Farnum directly owns 299,038 ordinary shares of Theravance Biopharma.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Positives
- The vesting of performance-based RSUs suggests that performance conditions were met, which could be viewed positively.
Negatives
- The withholding of shares to cover tax obligations reduces the number of shares directly held by the reporting person.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. Investors monitor these filings to gain insights into management's perspective on the company's stock.
Related Party Transactions
- The share withholding transaction to satisfy tax obligations is a transaction with the issuer.
Stakeholder Impact
- Shareholders may be interested in the transactions of company insiders as an indicator of management's confidence in the company.
Key Dates
| Date | Description |
|---|---|
| April 2, 2024 | Date the reporting person was granted a performance restricted stock unit award. |
| February 10, 2025 | Performance conditions were deemed achieved as to 5,283 RSUs. |
| February 20, 2025 | 15,810 shares withheld to satisfy tax obligations. |
| February 24, 2025 | Date of Form 4 filing. |
Keywords
Form 4, beneficial ownership, Theravance Biopharma, TBPH, restricted stock units, RSUs, insider trading, Rhonda Farnum
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.